INVESTORS & MEDIA HOME Download Mesoblast Corporate Backgrounder Mesoblast Corporate Backgrounder (2 MB) More Latest ASX Announcements 02 January 2020 Appendix 2A 02 January 2020 MSB Files GvHD Clinical Efficacy and Safety Data with US FDA 18 December 2019 DMC Completes Final Review of Phase 3 Heart Failure Trial 17 December 2019 Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Patients Surpasses the Number of Primary Endpoint Events for Trial Completion More Upcoming Events There are currently no events scheduled. More Stock Quote Exchange : Price : Change : Volume : Data as of 17 January 2020 5:11 PM EST Exchange : Price : Change : Volume : Data as of 17 January 2020 5:11 PM EST Copyright West LLC. Minimum 15 minutes delayed. Presentation to 2019 Annual General Meeting First Quarter Results Presentation 2019 Annual Report Annual Financial Results Presentation E-mail Alerts Sign up here to receive e-mail alerts.
17 December 2019 Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Patients Surpasses the Number of Primary Endpoint Events for Trial Completion
